Our colleagues at ML Strategies have provided a Health Care Weekly Preview. This week’s preview describes health insurers’ marketplace applications as well as the American Health Care Act (AHCA). Stay tuned for additional updates and analysis from ML Strategies.
As we gear up for a busy week in Washington, D.C., our colleagues at ML Strategies have provided a Health Care Weekly Preview. This week’s preview describes upcoming hearing on safety net health programs and prescription drug costs along with the progress of the American Health Care Act. Stay tuned for additional updates and analysis from ML Strategies.
In addition to yesterday’s post on the June session of Congress, our colleagues at ML Strategies have provided another weekly preview of Congressional activity for the week of June 5, 2017. The preview includes the upcoming schedule of the House and Senate, along with the looming issues of the American Health Care Act, the health care minibus, and tax reform. Stayed tuned for more upcoming previews and blog posts from the ML Strategies team!
Today, our colleagues at ML Strategies provided another installment of their Health Care Weekly Preview. The preview highlights upcoming activity in the House and Senate and other hot topics on the Hill. Highlights this week include the potential of a government shutdown, uncertainty around cost-sharing reductions for the 2018 plan year, and scheduled mark-ups by the Senate HELP Committee.
For an outlook on health care policy in the coming months in Congress, ML Strategies provided their insight in our prior post.
ML Strategies has provided a Spring Cheat Sheet previewing the coming months in health care policy in the 115th Congress. The Cheat Sheet addresses attempts to amend the American Health Care Act, funding for the federal government, the heath insurance marketplace, FDA user fee acts, and the health care minibus. The full Cheat Sheet is available here. Stay tuned for upcoming coverage of the health care policy actions (and inactions) in Washington, D.C.
ML Strategies has published the first installment of a new weekly preview, designed to give you quick overview of health happenings in the coming week. The preview highlights upcoming activity in the House and Senate and other hot topics on the Hill.
Spoiler alert: the confirmation processes for Dr. Scott Gottlieb (FDA) and Judge Neil Gorsuch (Supreme Court) will get a lot of attention this week.
See HERE for this week’s preview and be sure to stay tuned in the coming weeks.
This week, in their “Future of the Affordable Care Act” series on our Employment Matters blog, my colleagues Alden Bianchi and Edward Lenz provided an analysis of the major provisions of the American Health Care Act (“AHCA”).
Introduced on March 6, 2017, the AHCA is the first concrete legislative proposal detailing the initial provisions designed to repeal and replace the Affordable Care Act. As Alden and Ed discuss, the bill currently is the subject of widespread media scrutiny and intense criticism. The bill is not final and will likely face numerous changes, including the last minute proposals changes of the past 48 hours. The March 6th version offers an outline of Republican priorities in the regulation of health and health care financing, which include a strong bias in favor of market-based solutions and aversion to most (but not all) government intervention in the health care markets.
Check out their full analysis on The Future of the Affordable Care Act Week 7: The American Health Care Act, here. Continue Reading Future of the Affordable Care Act and the American Health Care Act
As we’ve previously discussed on Health Law and Policy Matters, agencies within the Department of Health and Human Services (DHHS) pushed through several final rules towards the end of the Obama Administration (see here and here). However, since taking office, President Trump has followed through on his campaign promise to significantly roll back Federal regulations and has taken several actions aimed at slowing and reversing agency regulatory processes, including processes at the DHHS sub-agencies CMS and FDA. These executive actions are creating a climate of uncertainty for regulated industries and their stakeholders. Continue Reading Trump Executive Orders Create Uncertainty for Health Care & Pharmaceutical Industries
For Health Care stakeholders, ML Strategies considers priorities that have been identified by the Trump Administration and the Republican-controlled Congress, and forecasts possible legislative and administrative actions to move their agendas along. We all know that the ACA is a target, and whether the chosen path forward is repeal and replace, or repair and rebuild, there are some key components of the law that are vital to a healthy marketplace. ML Strategies outlines some strategies and tactics we might see in the coming weeks.
In addition to ACA repeal, the Health Care Outlook also discusses key Administration appointees for HHS, CMS and FDA, as well as potential policy advisors. There are also a number of Congressional acts up for reauthorization – the “UFAs” for FDA, CHIP and Medicare outpatient therapy caps – each important in its own right, but which also creates opportunities for ‘ride-along’ policy initiatives.
Finally, ML Strategies looks to what may happen to the ACA cost-sharing reductions with the House v. Burwell litigation, and considers whether Telemedicine might provide an opportunity for this new Congress to work together, across party lines.
Join us in New York on Tuesday, January 24th, for a discussion on FDA priorities in 2017 and the potential impact on companies in the health care and life sciences industries. In a joint presentation from Mintz Levin and ML Strategies, my colleagues, Bethany Hills, Joanne Hawana, and Rodney Whitlock, will discuss the following topics:
- President Trump’s plans for FDA reform
- Expected health care activity in the 115th Congress
- Changing FDA regulatory priorities
- Practical implications for industry
We hope you will join us! The program will run from 5:30 – 6:30, with a cocktail reception to follow. Click here to register.
In the meantime, you can continue to follow our coverage of recent FDA developments here.